Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2021 08:16 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign erhåller utökat marknadsgodkännande av amerikanska läkemedelsverket för OssDsign Cranial PSI

STOCKHOLM, SVERIGE 4 oktober 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign AB har erhållit ett utökat marknadsgodkännande av det amerikanska...
October 04, 2021 08:16 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI

STOCKHOLM, SWEDEN, 4 October 2021 Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign AB has received an expanded marketing authorization from the...
September 09, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign inkluderar första patienten i en klinisk studie av det syntetiska bengraftet OssDsign Catalyst

STOCKHOLM, SVERIGE 9 september 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign AB har inkluderat den första patienten till bolagets kliniska studie...
September 09, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst

STOCKHOLM, SWEDEN – September 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial...
August 19, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari – juni 2021

STOCKHOLM – den 19 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - juni 2021. Den fulla rapporten är tillgänglig på bolagets hemsida. ...
August 19, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report - January-June 2021

STOCKHOLM – 19 August 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2021. The full report is available on the Company's website. “The...
August 16, 2021 09:51 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign lanserar bengraftsubstitutet OssDsign Catalyst i USA

STOCKHOLM, SVERIGE 16 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolagets portföljbolag OssDsign AB har lanserat OssDsign Catalyst i USA. Produkten är ett...
August 16, 2021 09:51 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market

STOCKHOLM, SWEDEN – August 16, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has launched OssDsign Catalyst in the U.S. The product is...
August 12, 2021 10:21 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Aprea Therapeutics meddelar att FDA beslutat om uppehåll i bolagets kliniska studieprogram

STOCKHOLM, SVERIGE 12 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att det amerikanska läkemedelsverket FDA har utfärdat ett clinical hold för portföljbolaget Aprea...
August 12, 2021 10:21 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program

STOCKHOLM, SWEDEN – August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics...